These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Estimation of surface state of poly(ethylene glycol)-coated liposomes using an aqueous two-phase partitioning technique. Moribe K; Maruyama K; Iwatsuru M Chem Pharm Bull (Tokyo); 1997 Oct; 45(10):1683-7. PubMed ID: 9353897 [TBL] [Abstract][Full Text] [Related]
11. Improved retention of idarubicin after intravenous injection obtained for cholesterol-free liposomes. Dos Santos N; Mayer LD; Abraham SA; Gallagher RC; Cox KA; Tardi PG; Bally MB Biochim Biophys Acta; 2002 Apr; 1561(2):188-201. PubMed ID: 11997119 [TBL] [Abstract][Full Text] [Related]
12. Factors influencing the retention and chemical stability of poly(ethylene glycol)-lipid conjugates incorporated into large unilamellar vesicles. Parr MJ; Ansell SM; Choi LS; Cullis PR Biochim Biophys Acta; 1994 Oct; 1195(1):21-30. PubMed ID: 7918562 [TBL] [Abstract][Full Text] [Related]
13. Prolonged circulation time in vivo of large unilamellar liposomes composed of distearoyl phosphatidylcholine and cholesterol containing amphipathic poly(ethylene glycol). Maruyama K; Yuda T; Okamoto A; Kojima S; Suginaka A; Iwatsuru M Biochim Biophys Acta; 1992 Sep; 1128(1):44-9. PubMed ID: 1390877 [TBL] [Abstract][Full Text] [Related]
14. Binding and uptake of liposomes containing a poly(ethylene glycol) derivative of cholesterol (stealth liposomes) by the macrophage cell line J774: influence of PEG content and its molecular weight. Vertut-Doï A; Ishiwata H; Miyajima K Biochim Biophys Acta; 1996 Jan; 1278(1):19-28. PubMed ID: 8611602 [TBL] [Abstract][Full Text] [Related]
15. Characterization of cationic liposome formulations designed to exhibit extended plasma residence times and tumor vasculature targeting properties. Ho EA; Ramsay E; Ginj M; Anantha M; Bregman I; Sy J; Woo J; Osooly-Talesh M; Yapp DT; Bally MB J Pharm Sci; 2010 Jun; 99(6):2839-53. PubMed ID: 20091826 [TBL] [Abstract][Full Text] [Related]
16. A targeted liposome delivery system for combretastatin A4: formulation optimization through drug loading and in vitro release studies. Nallamothu R; Wood GC; Kiani MF; Moore BM; Horton FP; Thoma LA PDA J Pharm Sci Technol; 2006; 60(3):144-55. PubMed ID: 17089683 [TBL] [Abstract][Full Text] [Related]
17. Controlled biodistribution of galactosylated liposomes and incorporated probucol in hepatocyte-selective drug targeting. Hattori Y; Kawakami S; Yamashita F; Hashida M J Control Release; 2000 Dec; 69(3):369-77. PubMed ID: 11102677 [TBL] [Abstract][Full Text] [Related]
18. Use of polyglycerol (PG), instead of polyethylene glycol (PEG), prevents induction of the accelerated blood clearance phenomenon against long-circulating liposomes upon repeated administration. Abu Lila AS; Nawata K; Shimizu T; Ishida T; Kiwada H Int J Pharm; 2013 Nov; 456(1):235-42. PubMed ID: 23928149 [TBL] [Abstract][Full Text] [Related]
19. Docetaxel-loaded liposomes: The effect of lipid composition and purification on drug encapsulation and in vitro toxicity. Pereira S; Egbu R; Jannati G; Al-Jamal WT Int J Pharm; 2016 Nov; 514(1):150-159. PubMed ID: 27863659 [TBL] [Abstract][Full Text] [Related]
20. Lipid-polymer hybrid nanoparticles as a new generation therapeutic delivery platform: a review. Hadinoto K; Sundaresan A; Cheow WS Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):427-43. PubMed ID: 23872180 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]